H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of Avadel Pharmaceuticals (AVDL) with a Buy rating and $22 price target The firm believes Avadel could exceed 4,000 narcolepsy patients on therapy by the end of next year. The company company is positioned to achieve the upper end of its guidance range this year, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel announces appeals court decision upholding FDA approval of LUMRYZ
- Avadel Under Fire as Activist Investor Seeks to Unthrone the Board
- Avadel Pharmaceuticals Wins Appeal on LUMRYZ Approval
- Avadel Pharmaceuticals: Promising Outlook with Orphan Drug Designation and Market Expansion for LUMRYZ
- Avadel Pharmaceuticals Receives FDA Orphan Drug Designation